We are a startup company which owns IP for the use of the molecule sphingosine as a nasal spray to prevent 1) infections cause by rhinovirus (80% of the causes of the common cold) and 2) invasion of SARS-CoV-2 by preventing the binding of the SARS-CoV-2 spike protein to its cellular receptor ACE2.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Wyoming
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
Sphingosine
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
